glp-1 constipation Constipation from GLP-1 Injections -

In 2014, the FDA approved the first of these drugs specifically for weight loss for people with a BMI of 30 and above or a BMI of at least 27 with one weight-related comorbid disease, which affects more than half the U.S

Results vary between individuals

Additionally, some novel GLP-1s hold promise for improved tolerability, as evidenced by Structure Therapeutics phase 2 data for GSBR-1290, which demonstrated encouraging results in terms of AEs and discontinuation rates

For those using injectable compounds, the peptide injections guide covers technique, while the dosage calculation guide and peptide dosage chart ensure accuracy

Most Ozempic and Wegovy side effects are mild to moderate in severity

As a result, even patients below the typical BMI threshold for GLP-1 as a weight loss treatment may still benefit from the same active ingredient